The most common grade @-@ adverse events were peripheral neuropathy ( in @ -LSB- @ % -RSB- of @ patients who received chemotherapy plus cetuximab vs ten -LSB- @ % -RSB- of @ who received chemotherapy alone ) , neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and increased aminotransferase concentrations ( @ -LSB- @ % -RSB- vs ten -LSB- @ % -RSB- ) .